Lyrica Rivals Are Rolled Out In The US
Several generic rivals to Pfizer’s Lyrica have hit the US market following the anti-seizure and pain brand’s loss of exclusivity.
You may also be interested in...
India’s Laurus Labs reported a strong fourth quarter and financial year on the back of a COVID-19 related demand surge. The company expects the growth rate to continue and improve in the coming quarters.
Despite reporting a 37% drop in Upjohn’s first-quarter sales, Pfizer has insisted that the decline was consistent with its expectations for the business. Meanwhile, biosimilars sales have been boosted by US launches as sterile injectables and hospital medicines have seen a lift from COVID-19.
Pfizer's biosimilars franchise is well on its way to becoming a blockbuster business, three years after the company launched its first US biosimilar.